Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1946 1
1947 4
1948 4
1949 2
1950 6
1951 5
1952 4
1953 4
1954 1
1955 2
1956 2
1957 1
1959 6
1960 2
1961 5
1962 1
1963 2
1964 3
1965 1
1966 1
1967 5
1968 5
1969 34
1970 39
1971 53
1972 113
1973 173
1974 161
1975 218
1976 232
1977 226
1978 288
1979 297
1980 309
1981 326
1982 394
1983 445
1984 506
1985 535
1986 474
1987 443
1988 480
1989 519
1990 497
1991 459
1992 468
1993 462
1994 411
1995 381
1996 413
1997 392
1998 397
1999 388
2000 379
2001 370
2002 375
2003 347
2004 377
2005 401
2006 444
2007 440
2008 432
2009 439
2010 508
2011 534
2012 569
2013 592
2014 623
2015 629
2016 670
2017 672
2018 683
2019 666
2020 808
2021 859
2022 827
2023 876
2024 372

Text availability

Article attribute

Article type

Publication date

Search Results

22,970 results

Results by year

Filters applied: . Clear all
Page 1
Bleomycin.
Lazo JS. Lazo JS. Cancer Chemother Biol Response Modif. 1999;18:39-45. Cancer Chemother Biol Response Modif. 1999. PMID: 10800476 Review. No abstract available.
Bleomycin.
Lazo JS, Sebti SM. Lazo JS, et al. Cancer Chemother Biol Response Modif. 1997;17:40-5. Cancer Chemother Biol Response Modif. 1997. PMID: 9551207 Review. No abstract available.
Bleomycin, a review.
Crooke ST, Bradner WT. Crooke ST, et al. J Med. 1976;7(5):333-428. J Med. 1976. PMID: 64579 Review. No abstract available.
Bleomycin and the skin.
Yamamoto T. Yamamoto T. Br J Dermatol. 2006 Nov;155(5):869-75. doi: 10.1111/j.1365-2133.2006.07474.x. Br J Dermatol. 2006. PMID: 17034512 Review.
Bleomycin is frequently used as a chemotherapeutic agent to treat various kinds of malignancy. However, the cytotoxic effects of bleomycin cause a number of adverse responses, in particular in the lung and the skin. ...
Bleomycin is frequently used as a chemotherapeutic agent to treat various kinds of malignancy. However, the cytotoxic effects of b …
Bleomycin-Induced Flagellate Dermatitis: Revisited.
Verma P, Rajaram S, Heda A, Sundriyal D, Tiwari P, Sahoo I, Panta S, Bordoloi M, Bhan H, Sharma D. Verma P, et al. Cureus. 2022 Sep 16;14(9):e29221. doi: 10.7759/cureus.29221. eCollection 2022 Sep. Cureus. 2022. PMID: 36258994 Free PMC article.
Flagellate dermatitis caused by bleomycin is a rare side effect with a distinctive pattern of whip-like, linear streaks. The clinical presentation has become uncommon nowadays as bleomycin use in conventional chemotherapy regimens has decreased. ...
Flagellate dermatitis caused by bleomycin is a rare side effect with a distinctive pattern of whip-like, linear streaks. The clinical …
Bleomycin.
Bennett JM, Reich SD. Bennett JM, et al. Ann Intern Med. 1979 Jun;90(6):945-8. doi: 10.7326/0003-4819-90-6-945. Ann Intern Med. 1979. PMID: 87142
Bleomycin was approved by the Food and Drug Administration in 1975 for therapy against squamous cell carcinomas, testicular cancers, and malignant lymphomas. ...Because of associated toxicity involving the lung and mucous membranes, bleomycin should be used cautious …
Bleomycin was approved by the Food and Drug Administration in 1975 for therapy against squamous cell carcinomas, testicular cancers, …
Bleomycin in non-Hodgkin's lymphoma.
Bayer RA, Gaynor ER, Fisher RI. Bayer RA, et al. Semin Oncol. 1992 Apr;19(2 Suppl 5):46-52; discussion 52-3. Semin Oncol. 1992. PMID: 1384144 Review.
Bleomycin is a cell-cycle--specific chemotherapeutic agent, with several interesting properties, that lends itself to use in combination chemotherapeutic protocols, especially those for malignant lymphomas. In the following article, bleomycin's use as a single agent …
Bleomycin is a cell-cycle--specific chemotherapeutic agent, with several interesting properties, that lends itself to use in combinat …
Bleomycin.
Lester EP, Matz GJ. Lester EP, et al. Otolaryngol Head Neck Surg (1979). 1979 Jul-Aug;87(4):399-400. doi: 10.1177/019459987908700401. Otolaryngol Head Neck Surg (1979). 1979. PMID: 92001 No abstract available.
The Interaction of the Metallo-Glycopeptide Anti-Tumour Drug Bleomycin with DNA.
Murray V, Chen JK, Chung LH. Murray V, et al. Int J Mol Sci. 2018 May 4;19(5):1372. doi: 10.3390/ijms19051372. Int J Mol Sci. 2018. PMID: 29734689 Free PMC article. Review.
In this review, the properties of bleomycin are examined, especially the interaction of bleomycin with DNA. A Fe(II)-bleomycin complex is capable of DNA cleavage and this process is thought to be the major determinant for the cytotoxicity of bleomycin. …
In this review, the properties of bleomycin are examined, especially the interaction of bleomycin with DNA. A Fe(II)-bleomy …
Bleomycin-induced pulmonary toxicity in chemotherapy for testicular cancer.
Kawai K, Akaza H. Kawai K, et al. Expert Opin Drug Saf. 2003 Nov;2(6):587-96. doi: 10.1517/14740338.2.6.587. Expert Opin Drug Saf. 2003. PMID: 14585067 Review.
Today, bleomycin is commonly used in chemotherapy for various tumour types. ...Several clinical trials have focused on eliminating bleomycin from the regimen or reducing the bleomycin dose for testicular cancer patients with good prognosis. ...
Today, bleomycin is commonly used in chemotherapy for various tumour types. ...Several clinical trials have focused on eliminating …
22,970 results
You have reached the last available page of results. Please see the User Guide for more information.